Here’s a roundup of the latest news coverage from Drug Topics®.
Empagliflozin Reduces Risk of CV Death, Hospitalization for Heart Failure With Preserved Ejection Fraction
The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.
COVID-19 Antibody Response in Fully Vaccinated Patients With Cancer
Patients with cancer with complete COVID-19 vaccinations demonstrated a high rate of antibodies, according to the study.
The Successes and Challenges of the Diabetes Prevention Program in California Medi-Cal
Kenrik Duru, MD, MSHS presented a model of future projections of Medi-Cal on Diabetes Prevention Programs through current performance measures and struggles identified.
Education Can Help Mitigate Parental Concern Over Flu Vaccination for Children With Diabetes
Educating families to alleviate fear in pediatric populations regarding the flu vaccine will improve the vaccination rate and protect high-risk children. Due to the negative effects of the flu in children with diabetes, it is vital that at-risk youth be vaccinated.
New Diversity Policy Adopted by American Medical Association
The policy is part of the organization’s commitment to racial justice and equity.
Novel Antifungal Treatment Approved for Vaginal Candidiasis
On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.
Pharma Makers Hike Drug Prices 3.1% in July
The biggest price increase was a 9.5% rise for Zogenix’s Fintepla (fenfluramine), used to treat seizures associated with Dravet syndrome.